Latest news with #FulgentGenetics
Associated Press
25-05-2025
- Business
- Associated Press
FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--May 24, 2025-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. ('Fulgent' or 'the Company') (NASDAQ: FLGT ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Fulgent disclosed as part of its annual report filed with the SEC on February 28, 2025, that it had received a civil investigative demand from the DOJ regarding potentially false claims filed under the Uninsured Program. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at [email protected]. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. View source version on CONTACT: The Schall Law Firm Brian Schall, Esq. 310-301-3335 [email protected] KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Schall Law Firm Copyright Business Wire 2025. PUB: 05/24/2025 09:19 PM/DISC: 05/24/2025 09:19 PM
Associated Press
16-05-2025
- Business
- Associated Press
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ('Wolf Haldenstein'), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). Key Details: Contact Information Firm: Wolf Haldenstein Adler Freeman & Herz LLP Primary Contact: Gregory Stone, Director of Case and Financial Analysis Email: mailto:[email protected] or [email protected] Phone: (800) 575-0735 or (212) 545-4774 This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
11-04-2025
- Business
- Yahoo
Fulgent Genetics (NASDAQ:FLGT) shareholders have endured a 69% loss from investing in the stock three years ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term Fulgent Genetics, Inc. (NASDAQ:FLGT) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 69% drop in the share price over that period. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Fulgent Genetics isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. In the last three years Fulgent Genetics saw its revenue shrink by 53% per year. That means its revenue trend is very weak compared to other loss making companies. Arguably, the market has responded appropriately to this business performance by sending the share price down 19% (annualized) in the same time period. When revenue is dropping, and losses are still costing, and the share price sinking fast, it's fair to ask if something is remiss. After losing money on a declining business with falling stock price, we always consider whether eager bagholders are still offering us a reasonable exit price. You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. If you are thinking of buying or selling Fulgent Genetics stock, you should check out this free report showing analyst profit forecasts . Fulgent Genetics shareholders are down 18% for the year, but the market itself is up 1.4%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 3% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - Fulgent Genetics has 1 warning sign we think you should be aware of. Fulgent Genetics is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
01-03-2025
- Business
- Yahoo
Fulgent Genetics Full Year 2024 Earnings: EPS Beats Expectations
Revenue: US$283.5m (down 2.0% from FY 2023). Net loss: US$42.7m (loss narrowed by 75% from FY 2023). US$1.41 loss per share (improved from US$5.64 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 17%. Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are down 6.1% from a week ago. We should say that we've discovered 1 warning sign for Fulgent Genetics that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
01-03-2025
- Business
- Yahoo
Fulgent Genetics Full Year 2024 Earnings: EPS Beats Expectations
Revenue: US$283.5m (down 2.0% from FY 2023). Net loss: US$42.7m (loss narrowed by 75% from FY 2023). US$1.41 loss per share (improved from US$5.64 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 17%. Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Healthcare industry in the US. Performance of the American Healthcare industry. The company's shares are down 6.1% from a week ago. We should say that we've discovered 1 warning sign for Fulgent Genetics that you should be aware of before investing here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
